Pharsight

Cibinqo is owned by Pfizer.

Cibinqo contains Abrocitinib.

Cibinqo has a total of 3 drug patents out of which 0 drug patents have expired.

Cibinqo was authorised for market use on 14 January, 2022.

Cibinqo is available in tablet;oral dosage forms.

Cibinqo can be used as treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable.

Drug patent challenges can be filed against Cibinqo from 2026-01-14.

The generics of Cibinqo are possible to be released after 19 February, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9035074	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (10 years from now)
US9545405	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (10 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (10 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 2026-01-14

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL